The Allure To The Immune Checkpoint Inhibitors
Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses The Allure To The Immune Checkpoint Inhibitors. At Kidney Cancer Association National Patient ...
Author: kidneycancer
Added: 10/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 5, 2018 Category: Cancer & Oncology Source Type: podcasts
ASSURE, S-TRAC, ATLAS, & PROTECT Trials
Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses ASSURE, S-TRAC, ATLAS, & PROTECT Trials. At Kidney Cancer Association National Patient Septemb...
Author: kidneycancer
Added: 10/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 5, 2018 Category: Cancer & Oncology Source Type: podcasts
Targeting plasticity pathways for novel therapy in prostate cancer
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Andrew Armstrong, MD, from Duke University, Durham, NC, highlights the need for novel therapies targeting plasticity pathways ...
Author: VJOncology
Added: 09/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Understanding bone metastases formation in patients with prostate cancer
Bone metastases are present in the majority of patients with prostate cancer and are the main cause of mortality in these patients. Here, Andrew Armstrong, MD, from Duke University, Durham, NC, discus...
Author: VJOncology
Added: 09/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 7, 2018 Category: Cancer & Oncology Source Type: podcasts
The impact of PSA in prostate cancer and its limitations
The use of prostate-specific antigen (PSA) levels as a diagnostic test for prostate cancer has significantly reduced mortality rates, as well as reducing the number of patients diagnosed with metastat...
Author: VJOncology
Added: 09/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Debating the future of prostate cancer management
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan, Italy, debates the benefits of abiraterone compared t...
Author: VJOncology
Added: 09/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 6, 2018 Category: Cancer & Oncology Source Type: podcasts
FALCON: radiopharmaceuticals for the management of recurrent prostate cancer
Speaking at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Eugene Teoh, MBBS, MRCP, from the University of Oxford, Oxford, UK, introduces a pre-planned analysis of the FALCON tri...
Author: VJOncology
Added: 09/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)
Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Lehtinen, assessing the benefit of adjuvant docetaxel for patients after radiation for patients with high o...
Author: BeaconMedIC
Added: 08/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2018 Category: Cancer & Oncology Source Type: podcasts
What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)
Dr. Daniel Goldstein reviews data on the positive predictive value of PET PSMA imaging in patients with biochemically relapsed prostate cancer, as presented by Wolfgang Fendler & colleagues at ASC...
Author: BeaconMedIC
Added: 08/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 28, 2018 Category: Cancer & Oncology Source Type: podcasts
New Data & amp; Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone for molecularly unselected metastatic prostate cancer, along with pr...
Author: BeaconMedIC
Added: 08/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 28, 2018 Category: Cancer & Oncology Source Type: podcasts
Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)
Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the implications of trials that fail in phase III despite looking ex...
Author: BeaconMedIC
Added: 08/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Changing the sequence of therapies in prostate cancer: looking ahead
With the positive results from recent trials like SPARTAN (NCT01946204) and PROSPER (NCT02003924), it is likely that drugs typically associated with metastatic castration-resistant prostate cancer (mC...
Author: VJOncology
Added: 08/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Cabazitaxel safe and effective in mCRPC
After promising efficacy data from the TROPIC trial (NCT00417079), cabazitaxel was approved for use in metastatic castration-resistant prostate cancer (mCRPC) post-docitaxel therapy. Until now, howeve...
Author: VJOncology
Added: 08/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonged duration of radium-223 (Xofigo) compared to standard dosing for 6 months with ...
Author: BeaconMedIC
Added: 08/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a plac...
Author: BeaconMedIC
Added: 08/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 17, 2018 Category: Cancer & Oncology Source Type: podcasts
